Is DMFS up or down today?
DMFS is down 1.12% today, last at 312.01. This stock moved -1.12% versus the prior close.
DMFS · DMFS
DMFS (DMFS) is trading at 312.01, down 1.12% on the session. DMFS sits at the 50% mark of its 52-week range.
Leading the coverage: “mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Melanoma - Targeted Oncology” (Google News Company, 20d ago).
DMFS trades on a trailing P/E of 31.2.
Analyst firms are mostly reiterating — no strong directional shift lately.
DMFS is down 1.12% today, last at 312.01. This stock moved -1.12% versus the prior close.
Leading the coverage: “mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Melanoma - Targeted Oncology” (Google News Company, 20d ago). Dominant story: mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Melanoma - Targeted Oncology (1 source, neutral) RSI unavailable Price sits at 50% of its 52-week range Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Melanoma - Targeted Oncology
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma - OncLive
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano - Business Wire
DMFs vs FPIs: Beyond the Rhetoric - Moneylife
DMFs vs FPIs: Beyond the rhetoric on India's changing equity market - Business Standard